Verily joins up with Duke, Stanford to enlist an army of consumers to put its next-gen sensor tech to the test — and in the public eye
Verily Study Watch via Verily
What can a new generation of wearable tech and biosensors teach us about disease?
Verily, formerly Google Life Sciences, is developing and marketing this tech. And it’s putting the company right at the crossroads between the biopharma industry and the public.
With considerable fanfare it’s announcing a new program with Duke University and Stanford to recruit 10,000 participants in a study to answer that question — using this new tech to gather data to provide a baseline of information on healthy subjects and how they transition to a disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
